Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-06-07
2005-06-07
Helms, Larry R. (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S387300, C435S320100
Reexamination Certificate
active
06903203
ABSTRACT:
An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.
REFERENCES:
patent: 6277599 (2001-08-01), Copley et al.
patent: 633029 (1995-10-01), None
patent: WO 92/01059 (1992-01-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 95/15341 (1995-06-01), None
patent: WO 96/11013 (1996-04-01), None
Chaudhary et a., Nature 339:394, 1989.
Paul, Fundamental Immunology, Raven Press, NY, chapter 8, p. 242, 1993.
Abraham, “Screening and kinetic analysis of recombinant anti-CEA antibody fragments,”Journal of Immunological Methods, 183, 1995, pp. 119-125, Elsevier Science B.V.
Accolla, “Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines,”Proc. Natl. Acad. Sci., 77, 1980, pp. 563-566.
Banjo, “Intermolecular heterogeneity of the Carcinoembryonic Antigen,”Cancer Research, 34, Aug. 1974, pp. 2114-2121.
Chandrasekaran, “Isolation and Structures of the Oligosaccharaide Units of Carcinoembryonic Antigen,”The Journal of Biological Chemistry, 258, 1983, pp. 7213-7222, U.S.A.
Chournoyer, “Transcription of Genes of the Carcinoembryonic Antigen Family in Malignant and Nonmalignant Human Tissues,”Cancer Research, 48, 1988, pp. 3153-3157.
Durbin, “An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3,”Proc. Natl. Acad. Sci., 91, 1994, pp. 4313-4317.
Haggarty, “Epitopes of Carcinoembryonic Antigen Defined by Monoclonal Antibodies Prepared from Mice Immunized with Purified Carcinoembryonic Antigen or HCT-8R Cells,”Cancer Research, 46, 1986, pp. 300-309.
Hammarstrom, “Antigenic Sites in Caracinoembryonic Antigen,”Cancer Research, 49, 1989, pp. 4852-4858.
Hansen, “Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen,”Cancer, 71, Jun. 1993, pp. 3478-3485.
Hedin, “Specificities and binding properties of eight monoclonal antibodies against carcinoembryonic antigen,”Molecular Immunology, 19, 1982, pp. 1641-1648, Pergamon Press Ltd., U.K.
Hefta, “Expression of Carcinoembryonic Antigen and Its Predicted Immunoglobulin-like Domains in HeLa Cells for Epitope Analysis,”Cancer Research, 52, Oct. 1992, 5647-5655.
Konstadoulakis, “The Presence of Anti-Carcinoembryonic Antigen (CEA) Antibodies in the Sera of Patients with Gastrointestinal Malignancies,”Journal of Clinical Immunology, 14, 1994, pp. 310- 313.
Kuroki, “Purification and Characterization of Carcinoembryonic Antigen-related Antigens in Normal Adult Feces,”Cancer Research, 41, Feb. 1981, 713-718.
Kupchik, Monoclonal Antibodies to Carcinoembryonic Antigen Produced by Somatic Cell Fusion,Cancer Research, 41, Sep. 1981, pp. 3306-3310.
Oikawa, “Primary Structure of Human Carcinoembryonic Antigen (CEA) Deduced from cDNA Sequence,”Biochemicals and Biophysical Research Communications, 142, 1987, pp. 511-518.
Rogers, “Somatic-Cell Hybrids Producing Antibodies Against CEA,”Br. J. Cancer, 43, 1981, pp. 1-4.
Thomas, “A Peptide Sequence on Carcinoembryonic Antigen Binds to a 80kD Protein on Kupffer Cell,”Biochemicals and Biophysical Research Communications, 188, 1992, pp. 671-677.
D. Blakely et al., “Anti-tumor effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.”,British Journal of Cancer,Nov. 1995, pp. 1083-1088, vol. 72, No. 5, Basingstoke, GB.
M. Michael et al., “In vitro and in vivo characterization of a recombinant carboxypeptidase G2:anti-CEA scFv fusion protein,”Immunotechnology,1996, pp. 47-57, vol. 2, No. 1, Amsterdam, NL.
S. Leung et al.., “Bacterial expression of a keptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment,”Cancer Research,Dec. 1, 1995, pp. 5968S-5972S, vol. 55, No. 23, suppl., Baltimore, MD, USA.
K. Bosslet et al.., “Tumor-selective prodrug activation by fusion protein-mediated catalysis,”Cancer Research,Apr. 1, 1994, pp. 2151-2159, vol. 54, No. 7, Baltimore, MD, USA.
Copley Clive Graham
Edge Michael Derek
Emery Stephen Charles
AstraZeneca UK Ltd.
Helms Larry R.
Rothwell Figg Ernst & Manbeck
LandOfFree
Monoclonal antibody to CEA, conjugates comprising said... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody to CEA, conjugates comprising said..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody to CEA, conjugates comprising said... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3514073